Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.85 EUR | +1.50% | +4.43% | +18.95% |
08:11am | GSK : Sell rating from JP Morgan | ZD |
02:17am | U.S. FDA approves Akebia's anemia drug | RE |
Sales 2024 * | 31.56B 39.83B 36.91B | Sales 2025 * | 33.49B 42.28B 39.17B | Capitalization | 69.81B 88.12B 81.65B |
---|---|---|---|---|---|
Net income 2024 * | 5.6B 7.07B 6.55B | Net income 2025 * | 6.25B 7.89B 7.31B | EV / Sales 2024 * | 2.61 x |
Net Debt 2024 * | 12.57B 15.87B 14.7B | Net Debt 2025 * | 9.37B 11.83B 10.96B | EV / Sales 2025 * | 2.36 x |
P/E ratio 2024 * |
12.5
x | P/E ratio 2025 * |
11
x | Employees | 70,212 |
Yield 2024 * |
3.58% | Yield 2025 * |
3.86% | Free-Float | 92.08% |
Latest transcript on GSK plc
1 day | +2.22% | ||
1 week | +4.43% | ||
Current month | +1.76% | ||
1 month | +2.43% | ||
3 months | +17.71% | ||
6 months | +13.72% | ||
Current year | +18.95% |
Managers | Title | Age | Since |
---|---|---|---|
Emma Walmsley
CEO | Chief Executive Officer | 55 | 10-04-30 |
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
James Ford
CMP | Compliance Officer | - | 95-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
Jonathan Symonds
CHM | Chairman | 66 | 19-08-31 |
Urs Rohner
BRD | Director/Board Member | 65 | 14-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 19.85 | +1.50% | 890 |
24-03-27 | 19.55 | +0.35% | 477 |
24-03-26 | 19.48 | -0.59% | 1,668 |
24-03-25 | 19.6 | +0.84% | 2,425 |
24-03-22 | 19.44 | +0.86% | 560 |
Delayed Quote Deutsche Boerse AG, March 28, 2024 at 04:50 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.46% | 701B | |
+26.24% | 571B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 319B | |
+0.74% | 210B | |
+2.95% | 210B | |
-6.05% | 201B | |
-3.61% | 157B |
- Stock
- Equities
- Stock GSK plc
- Stock GSK plc - Deutsche Boerse AG